NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1464.70 10.60 (0.73%)

25.65% Gain from 52W Low

1.0M NSE+BSE Volume

NSE 30 Jun, 2026 11:28 AM (IST)

118,325.1

Market Cap

High in industry

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Search Inside the pdf :

Cipla Ltd.

14 May 2026

1464.70

0.73%

Cipla (HOLD): Mixed Earnings; exciting set of new products awaited

Hold: Cipla Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 1%/11%30% below estimates. Gross Margin reported 360 bps above; EBITDA Margin 176 bps below estimates

Number of FII/FPI investors decreased from 1052 to 964 in Mar 2026 qtr

Cipla Ltd.

14 May 2026

1464.70

0.73%

Cipla (CIPLA IN) Q4FY26 Result Update Weak US revenues, timely launches will be key Accumulate

Accumulate: Cipla Ltd.

Target

Prabhudas Lilladhar

Muted US sales: CIPLA's Q4FY26 revenues declined 3% YoY to INR 65.4bn, below our estimates. Domestic formulation reported strong growth of 15% YoY. Key therapies such as Respiratory, Urology, Anti diabetic and Cardiac outpaced the market. US sales contribution from gRevlimid and supply issues in gLanreotide. One Africa business reported growth of 21% YoY; whereas EM + EU markets were down 8% YoY. Healthy GMs, EBITDA miss: GMs stood at 66%, down 185bps YoY but up 280bps QoQ. CIPLA reported EBITDA of INR 9.5bn; down 38% YoY; 7% below our estimates. OPM up 19% YoY and 3% QoQ. Ex R&D cost other expenses were up 6% YoY. Resultant PAT...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

14 May 2026

1464.70

0.73%

Cipla Ltd.

Buy: Cipla Ltd.

Target

ICICI Direct

The revenues were largely in line except US where intensity was tad higher which was offset by higher growth in other geographies. The management is confident of better performance from India and US in the ensuing year with better performance in second half. FY26 was year of some consolidation mainly due to genericization of gRevlimid and problems in some of its Key Products in US geographies. Going forward, the management momentum to really accelerate in the US from H2FY27 with an aspiration to reach US$ 1 billion annual revenue run rate by exit quarter...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

24 Apr 2026

1464.70

0.73%

Launches to address concern on US growth; valuation attractive

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Cipla’s recent product approval of gOfev and gVentolin from the USFDA is likely to start allaying concerns arising on its US growth post the discontinuation of Lanreotide, loss of exclusivity in gRevlimid and regulatory issues at key plants in India.

Number of FII/FPI investors decreased from 1052 to 964 in Mar 2026 qtr

Cipla Ltd.

23 Apr 2026

1464.70

0.73%

Cipla gets USFDA nod for albuterol inhaler, strengthening US respiratory play

Neutral: Cipla Ltd.

Target

Motilal Oswal

Cipla received USFDA approval for the first AB-rated generic of Ventolin HFA (albuterol inhaler), giving it a first-to-market edge with pharmacy-level substitution in the US.

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

25 Jan 2026

1464.70

0.73%

Cipla (HOLD): A clear HOLD as valuation reflects pessimism

Hold: Cipla Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported -5.5%/-27.9%/-45% below our estimates. Ex of one-time cost, PAT reported 23% below our estimates

Cipla Ltd. has an average target of 1553.22 from 9 brokers.

Cipla Ltd.

24 Jan 2026

1464.70

0.73%

EBITDA/earnings decline YoY after 13 quarters

Neutral: Cipla Ltd.

Target

Motilal Oswal

CIPLA delivered an in-line revenue. However, it posted lower-than-expected EBITDA/PAT (21%/22% miss) for the quarter. After almost 13 quarters, CIPLA exhibited a YoY decline in EBITDA in 3QFY26.

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

23 Dec 2025

1464.70

0.73%

CIPLA LTD

Hold: Cipla Ltd.

Recommendation Target

Geojit BNP Paribas

Cipla Ltd delivered a steady Q2FY26 performance, supported by strong branded generics in India and continued leadership in its US respiratory business (albuterol MDI). The company's strategic focus on high-growth therapies such as obesity and diabetes (exclusive launch of Tirzepatide Yurpeak in India) underpins its long-term growth potential. However, near-term challenges remain, including the anticipated revenue erosion from the Revlimid cliff, increased R&D intensity weighing on margins, and execution risk related to timely approvals, which could limit earnings visibility and margin recovery in the medium term, thereby warranting a more...

Number of FII/FPI investors decreased from 1052 to 964 in Mar 2026 qtr

Cipla Ltd.

04 Nov 2025

1464.70

0.73%

Growth outlook intact despite near-term headwinds

Accumulate: Cipla Ltd.

Target

Deven Choksey

Cipla’s near-to-medium term outlook remains positive, underpinned by strong execution in domestic formulations and a visible ramp-up in complex generics and biosimilars in the U.S. market.